Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
Provided By GlobeNewswire
Last update: Feb 28, 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences.
Read more at globenewswire.com
